Recent Insider Transactions • Aug 13
Lead Independent Director recently sold €140k worth of stock On the 11th of August, Richard Prins sold around 8k shares on-market at roughly €17.59 per share. This transaction amounted to 27% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €232k more than they bought in the last 12 months. Reported Earnings • Aug 07
Second quarter 2026 earnings released: EPS: US$0.69 (vs US$0.66 in 2Q 2025) Second quarter 2026 results: EPS: US$0.69. Revenue: US$183.9m (up 5.4% from 2Q 2025). Net income: US$30.3m (down 2.2% from 2Q 2025). Profit margin: 17% (down from 18% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.5% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Pharmaceuticals industry in Germany. Annuncio • Jul 29
Amphastar Pharmaceuticals, Inc. to Report Q2, 2026 Results on Aug 06, 2026 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026 Annuncio • Jul 13
Amphastar Pharmaceuticals, Inc. Announces Board Changes, Effective July 9, 2026 Amphastar Pharmaceuticals, Inc. had its Board of Directors approve an increase to the authorized number of directors permitted to serve on the Board from ten to eleven directors and appointed Anthony Pierce to serve as a Class III director, to hold office until the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal, effective July 9, 2026. Mr. Pierce was not appointed to serve on any committees of the Board at this time. The Board also determined that Mr. Pierce does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that he is independent within the meaning of the listing standards of the Nasdaq Stock Market LLC. There are no arrangements or understandings between Mr. Pierce and any other person pursuant to which he was selected as a director of the Company. There are no transactions between Mr. Pierce and the Company that would be reportable under Item 404(a) of Regulation S-K. In connection with Mr. Pierce's appointment as a director, the Company will enter into its standard form of indemnification agreement with Mr. Pierce. Valuation Update With 7 Day Price Move • Jun 30
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to €18.71, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total loss to shareholders of 64% over the past three years. Annuncio • Jun 17
Amphastar Pharmaceuticals Inc Receives FDA Approval for Over-The-Counter Rextovy Naloxone Nasal Spray Amphastar Pharmaceuticals, Inc. received approval for another over-the-counter intranasal naloxone product, Rextovy, a 4 milligram naloxone hydrochloride nasal spray for the emergency treatment of opioid overdose. Consumers may directly purchase this product without a prescription in places such as pharmacies, convenience stores, and online. Rextovy is an additional life-saving medication approved by the FDA to reverse an opioid overdose to be sold directly to consumers and contains the same active ingredient as other naloxone nasal sprays. The availability of multiple approved formulations expands access and market availability, encourages competition that may reduce cost, and offers alternative sourcing options. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose. When using Rextovy, some people may experience symptoms when they regain consciousness following overdose reversal, such as shaking, sweating, nausea, or feeling angry. The product is safe to use even when it is uncertain whether opioids are present in the person's system. The product's packaging includes pictorial directions with five clear steps, including calling 911 after giving the first dose. The FDA granted the nonprescription approval to Amphastar Pharmaceuticals, Inc. Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. CFO, Executive VP of Finance, Treasurer & Director Bill Peters was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Annuncio • Apr 30
Amphastar Pharmaceuticals, Inc. to Report Q1, 2026 Results on May 07, 2026 Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026 Annuncio • Apr 14
Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026 Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2026. Annuncio • Feb 20
Amphastar Pharmaceuticals, Inc. to Report Q4, 2025 Results on Feb 26, 2026 Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 26, 2026 Annuncio • Oct 27
Amphastar Pharmaceuticals, Inc. to Report Q3, 2025 Results on Nov 06, 2025 Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2025 results After-Market on Nov 06, 2025 Annuncio • Jul 29
Amphastar Pharmaceuticals, Inc. to Report Q2, 2025 Results on Aug 07, 2025 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025 Annuncio • Jul 22
Amphastar Pharmaceuticals, Inc. Appoints David Gaugh to Serve as A Class I Director On July 18, 2025, the Board of Directors (the “Board”) of Amphastar Pharmaceuticals, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), approved an increase to the authorized number of directors permitted to serve on the Board from ten (10) to eleven (11) directors and appointed David Gaugh, to serve as a Class I director, to hold office until the Company’s 2026 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal, effective immediately. Mr. Gaugh was not appointed to serve on any committees of the Board at this time. Annuncio • Jun 30
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index Annuncio • Apr 30
Amphastar Pharmaceuticals, Inc. to Report Q1, 2025 Results on May 07, 2025 Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025 Annuncio • Apr 05
Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025 Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 02, 2025. Annuncio • Feb 21
Amphastar Pharmaceuticals, Inc. to Report Q4, 2024 Results on Feb 27, 2025 Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2024 results After-Market on Feb 27, 2025 New Risk • Nov 15
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (48% net debt to equity). Significant insider selling over the past 3 months (€241k sold). Reported Earnings • Nov 08
Third quarter 2024 earnings released: EPS: US$0.83 (vs US$1.01 in 3Q 2023) Third quarter 2024 results: EPS: US$0.83 (down from US$1.01 in 3Q 2023). Revenue: US$191.2m (up 5.9% from 3Q 2023). Net income: US$40.4m (down 18% from 3Q 2023). Profit margin: 21% (down from 27% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 3.4% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year whereas the company’s share price has increased by 35% per year. Annuncio • Oct 29
Amphastar Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024 New Risk • Sep 09
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: €241k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (52% net debt to equity). Significant insider selling over the past 3 months (€241k sold). Reported Earnings • Aug 08
Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.54 in 2Q 2023) Second quarter 2024 results: EPS: US$0.78 (up from US$0.54 in 2Q 2023). Revenue: US$182.4m (up 25% from 2Q 2023). Net income: US$37.9m (up 45% from 2Q 2023). Profit margin: 21% (up from 18% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Annuncio • Aug 01
Amphastar Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024 Annuncio • Jun 06
Amphastar Pharmaceuticals, Inc. Approves the Appointment of Howard Lee as Director Amphastar Pharmaceuticals, Inc. at its Annual General Meeting held on June 3, 2024, approved the appointment of Howard Lee as director to serve until the 2027 annual meeting of stockholders and until his or her successor is duly elected and qualified. Annuncio • May 23
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted approval for the company's Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, previously known as AMP-008. This product is for the treatment or prevention of bronchospasm in patients four years of age and older with irreversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients 4 years of age and older. The FDA determined that Amphastar's albuterol is bioequivalent and therapeutically equivalent to Teva Respiratory LLC's ProAir®? HFA(albuterol sulfate) Inhalation Aerosol. Amphastar plans to launch its Albuterol Sulfate Inhalation Aerosol in the third quarter of 2024. Reported Earnings • May 09
First quarter 2024 earnings released: EPS: US$0.90 (vs US$0.54 in 1Q 2023) First quarter 2024 results: EPS: US$0.90 (up from US$0.54 in 1Q 2023). Revenue: US$171.8m (up 23% from 1Q 2023). Net income: US$43.2m (up 66% from 1Q 2023). Profit margin: 25% (up from 19% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 36% per year, which means it is significantly lagging earnings growth. Annuncio • May 01
Amphastar Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024 Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024 Annuncio • Apr 13
Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024 Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 03, 2024, at 11:00 Pacific Standard Time. Agenda: To elect four Class II directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for our fiscal year ending December 31, 2024; to approve, on an advisory basis, the compensation of named executive officers; to approve the amendment and restatement of the Company’s 2015 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof. Recent Insider Transactions • Mar 08
Insider recently sold €543k worth of stock On the 5th of March, Michael Zasloff sold around 13k shares on-market at roughly €43.41 per share. This transaction amounted to 40% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.9m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €43.20, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 16x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 175% over the past three years. Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: US$2.85 (vs US$1.88 in FY 2022) Full year 2023 results: EPS: US$2.85 (up from US$1.88 in FY 2022). Revenue: US$644.4m (up 29% from FY 2022). Net income: US$137.5m (up 51% from FY 2022). Profit margin: 21% (up from 18% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has only increased by 48% per year, which means it is significantly lagging earnings growth. Annuncio • Feb 29
Amphastar Pharmaceuticals, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2023 Amphastar Pharmaceuticals, Inc. reported impairment of long-lived assets for the fourth quarter ended December 31, 2023. For the quarter, the company reported impairment of long-lived assets of $1,000. Annuncio • Feb 21
Amphastar Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 28, 2024 Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2023 results After-Market on Feb 28, 2024 Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €48.40, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 17x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 208% over the past three years. Recent Insider Transactions • Nov 17
Lead Independent Director recently sold €245k worth of stock On the 13th of November, Richard Prins sold around 5k shares on-market at roughly €49.08 per share. This transaction amounted to 13% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €2.2m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Nov 15
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to €52.50, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 228% over the past three years. Reported Earnings • Nov 09
Third quarter 2023 earnings released: EPS: US$1.01 (vs US$0.33 in 3Q 2022) Third quarter 2023 results: EPS: US$1.01 (up from US$0.33 in 3Q 2022). Revenue: US$180.6m (up 50% from 3Q 2022). Net income: US$49.2m (up 210% from 3Q 2022). Profit margin: 27% (up from 13% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Annuncio • Nov 02
Amphastar Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023 Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2023 results After-Market on Nov 08, 2023 Recent Insider Transactions • Aug 18
Insider recently sold €668k worth of stock On the 15th of August, Michael Zasloff sold around 13k shares on-market at roughly €52.37 per share. This transaction amounted to 29% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €1.6m more than they bought in the last 12 months. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €48.60, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 21x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 188% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €73.37 per share. New Risk • Aug 09
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Significant insider selling over the past 3 months (€734k sold). Reported Earnings • Aug 09
Second quarter 2023 earnings released: EPS: US$0.54 (vs US$0.35 in 2Q 2022) Second quarter 2023 results: EPS: US$0.54 (up from US$0.35 in 2Q 2022). Revenue: US$145.7m (up 18% from 2Q 2022). Net income: US$26.1m (up 51% from 2Q 2022). Profit margin: 18% (up from 14% in 2Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 50% per year, which means it is significantly lagging earnings growth. Annuncio • Aug 03
Amphastar Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2023 results After-Market on Aug 08, 2023 Valuation Update With 7 Day Price Move • Jul 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €57.00, the stock trades at a forward P/E ratio of 28x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 228% over the past three years. New Risk • Jul 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.1% average weekly change). Significant insider selling over the past 3 months (€734k sold). Valuation Update With 7 Day Price Move • Jun 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €49.40, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 170% over the past three years. Recent Insider Transactions • May 18
Insider recently sold €291k worth of stock On the 15th of May, Michael Zasloff sold around 8k shares on-market at roughly €38.80 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €3.8m more than they bought in the last 12 months. Reported Earnings • May 10
First quarter 2023 earnings released: EPS: US$0.54 (vs US$0.50 in 1Q 2022) First quarter 2023 results: EPS: US$0.54 (up from US$0.50 in 1Q 2022). Revenue: US$140.0m (up 16% from 1Q 2022). Net income: US$26.0m (up 7.3% from 1Q 2022). Profit margin: 19% (down from 20% in 1Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 24% per year, which means it is significantly lagging earnings growth. Annuncio • May 04
Amphastar Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 09, 2023 Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2023 results at 4:00 PM, US Eastern Standard Time on May 09, 2023 Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €32.00, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 18x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 100% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.56 per share. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: US$1.88 (vs US$1.30 in FY 2021) Full year 2022 results: EPS: US$1.88 (up from US$1.30 in FY 2021). Revenue: US$499.0m (up 14% from FY 2021). Net income: US$91.4m (up 47% from FY 2021). Profit margin: 18% (up from 14% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Reported Earnings • Nov 09
Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.61 in 3Q 2021) Third quarter 2022 results: EPS: US$0.33 (down from US$0.61 in 3Q 2021). Revenue: US$120.1m (up 7.1% from 3Q 2021). Net income: US$15.9m (down 46% from 3Q 2021). Profit margin: 13% (down from 26% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has only increased by 20% per year, which means it is significantly lagging earnings growth. Annuncio • Oct 29
Amphastar Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 07, 2022 Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2022 results After-Market on Nov 07, 2022 Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €30.40, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 14x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 53% over the past three years. Reported Earnings • Aug 10
Second quarter 2022 earnings released: EPS: US$0.35 (vs US$0.16 in 2Q 2021) Second quarter 2022 results: EPS: US$0.35 (up from US$0.16 in 2Q 2021). Revenue: US$123.5m (up 21% from 2Q 2021). Net income: US$17.3m (up 123% from 2Q 2021). Profit margin: 14% (up from 7.6% in 2Q 2021). Over the next year, revenue is forecast to grow 10%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year. Annuncio • Aug 10
Amphastar Pharmaceuticals, Inc. Announces Executive Changes On August 4, 2022, the Board of Directors of Amphastar Pharmaceuticals, Inc. upon the recommendation of the Nominating and Corporate Governance Committee of the Board approved an increase to the authorized number of directors permitted to serve on the Board from eight (8) to ten (10) directors and appointed each of William J. Peters, the Company’s Chief Financial Officer, Executive Vice President of Finance, and Treasurer, and Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, and Sales and Marketing (together with Mr. Peters, the “New Directors”), to serve as Class I directors, to hold office until the Company’s 2023 annual meeting of stockholders and until each such director’s successor is duly elected and qualified or until each such director’s earlier death, resignation or removal, effective immediately. The Board also determined that Diane G. Gerst does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director that, including Ms. Gerst, six of the Company’s current directors are independent of within the meaning of the listing standards of the Nasdaq Stock Market LLC. Annuncio • Aug 02
Amphastar Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2022 results After-Market on Aug 08, 2022 Valuation Update With 7 Day Price Move • Jun 08
Investor sentiment improved over the past week After last week's 16% share price gain to €38.80, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Pharmaceuticals industry in Germany. Total returns to shareholders of 129% over the past three years. Recent Insider Transactions • May 22
Chairman of the Board recently sold €3.5m worth of stock On the 19th of May, Ziping Luo sold around 109k shares on-market at roughly €32.11 per share. This was the largest sale by an insider in the last 3 months. This was Ziping's only on-market trade for the last 12 months. Reported Earnings • May 11
First quarter 2022 earnings released: EPS: US$0.50 (vs US$0.11 in 1Q 2021) First quarter 2022 results: EPS: US$0.50 (up from US$0.11 in 1Q 2021). Revenue: US$120.4m (up 17% from 1Q 2021). Net income: US$24.3m (up 381% from 1Q 2021). Profit margin: 20% (up from 4.9% in 1Q 2021). The increase in margin was primarily driven by higher revenue. Over the next year, revenue is forecast to grow 15%, compared to a 6.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year. Annuncio • May 04
Amphastar Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 09, 2022 Amphastar Pharmaceuticals, Inc. announced that they will report Q1, 2022 results After-Market on May 09, 2022 Annuncio • Apr 15
Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022 Amphastar Pharmaceuticals, Inc., Annual General Meeting, Jun 10, 2022, at 11:00 Pacific Standard Time. Agenda: To consider and elect three class III directors to hold office for a three-year term and until their respective successors are duly elected and qualified or until such director’s earlier death, resignation or removal; to consider and ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to consider and approve on an advisory basis, the compensation of our named executive officers; and to transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof. Reported Earnings • Mar 12
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: EPS: US$1.30 (up from US$0.03 in FY 2020). Revenue: US$437.8m (up 25% from FY 2020). Net income: US$62.1m (up US$60.7m from FY 2020). Profit margin: 14% (up from 0.4% in FY 2020). The increase in margin was driven by higher revenue. Post-clinical trial products Pre-registration: 5 Launched (during full year): 1 Revenue exceeded analyst estimates by 2.2%. Over the next year, revenue is forecast to grow 11%, compared to a 8.1% growth forecast for the pharmaceuticals industry in Germany. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 20% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 09
Third quarter 2021 earnings released: EPS US$0.61 (vs US$0.083 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$112.2m (up 35% from 3Q 2020). Net income: US$29.5m (up US$25.6m from 3Q 2020). Profit margin: 26% (up from 4.7% in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Executive Departure • Aug 24
Independent Director David Maris has left the company On the 19th of August, David Maris' tenure as Independent Director ended after 1.2 years in the role. As of June 2021, David still personally held 7.30k shares (€123k worth at the time). David is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 13.96 years. Annuncio • Aug 21
Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million. Amphastar Pharmaceuticals, Inc. (NasdaqGS:AMPH) entered into a share purchase agreement to acquire the remaining 15% stake in Amphastar Nanjing Pharmaceuticals, Co., Ltd., from Applied Physics & Chemistry Laboratories, Inc., Bill Zhang and Chongqing Zhang for $22.5 million on August 19, 2021. Pursuant to the terms of the transaction, Amphastar Pharmaceuticals, Inc., shall pay $18.9 million to Applied Physics & Chemistry Laboratories, Inc., $3.4 million to Bill Zhang and $0.21 million to Chongqing Zhang. Following completion of the transaction, Amphastar Pharmaceuticals, Inc., will own 100% of Amphastar Nanjing Pharmaceuticals, Co., Ltd. Reported Earnings • Aug 10
Second quarter 2021 earnings released: EPS US$0.16 (vs US$0.004 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.7m (up 19% from 2Q 2020). Net income: US$7.77m (up US$7.96m from 2Q 2020). Profit margin: 7.6% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Jun 13
Insider recently sold €76k worth of stock On the 9th of June, Rong Zhou sold around 5k shares on-market at roughly €16.07 per share. In the last 3 months, they made an even bigger sale worth €102k. Insiders have been net sellers, collectively disposing of €462k more than they bought in the last 12 months. Recent Insider Transactions • May 15
Insider recently sold €73k worth of stock On the 12th of May, Jacob Liawatidewi sold around 5k shares on-market at roughly €16.00 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €414k more than they bought in the last 12 months. Reported Earnings • May 08
First quarter 2021 earnings released: EPS US$0.11 (vs US$0.085 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$103.0m (up 22% from 1Q 2020). Net income: US$5.04m (up 28% from 1Q 2020). Profit margin: 4.9% (up from 4.7% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Annuncio • May 04
Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Morphine Sulfate Injection Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Morphine Sulfate injection 1mg/mL in the 30mL Pump-Jet® Prefilled Syringe System. It is indicated for the management of pain severe enough to require use of an opioid analgesic by Patient-Controlled Analgesia (PCA), only for use with a compatible Alaris® infusion device, and for which alternative treatments are inadequate. For the past 30 years, the company has sold and marketed the product under the “grandfather” exception to the FDA’s “Prescription Drug Wrap-Up” program. Reported Earnings • Mar 17
Full year 2020 earnings released: EPS US$0.03 (vs US$1.04 in FY 2019) The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: US$349.8m (up 8.5% from FY 2019). Net income: US$1.40m (down 97% from FY 2019). Profit margin: 0.4% (down from 15% in FY 2019). Post-clinical trial products Pre-registration: 6 Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Annuncio • Mar 10
Amphastar Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 15, 2021 Amphastar Pharmaceuticals, Inc. announced that they will report Q4, 2020 results After-Market on Mar 15, 2021 Is New 90 Day High Low • Feb 25
New 90-day low: €14.50 The company is down 2.0% from its price of €14.80 on 26 November 2020. The German market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €66.42 per share. Annuncio • Jan 28
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index Annuncio • Dec 30
Amphastar Announces Approval for Glucagon for Injection Kit, 1mg Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Glucagon is indicated for the treatment of severe hypoglycemia and is also used as a diagnostic aid. Amphastar’s newly approved synthetic peptide product was determined by the FDA to be bioequivalent and therapeutically equivalent to Eli Lilly’s Glucagon Emergency Kit for Low Blood Sugar, which has a recombinant DNA (rDNA)-origin. Amphastar plans to launch this Glucagon for Injection Emergency Kit, which it previously referred to as AMP-001, within two months. The Company currently has four ANDAs filed with the FDA, which are targeting products with a market size of approximately $1.4 billion, three biosimilar products in development targeting products with a market size of approximately $13.0 billion, and nine generic products in development targeting products with a market size of approximately $12.0 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2020. The Company is developing multiple proprietary pipeline products for injectable and intranasal dosage forms, including a new drug application for intranasal naloxone and intranasal epinephrine. Amphastar’s Chinese subsidiary, ANP, currently has 14 Drug Master Files, or DMF, on file with the FDA and is developing several additional DMFs. Is New 90 Day High Low • Nov 24
New 90-day low: €15.00 The company is down 12% from its price of €17.00 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €57.82 per share. Analyst Estimate Surprise Post Earnings • Nov 07
Revenue misses expectations Revenue missed analyst estimates by 8.6%. Over the next year, revenue is forecast to grow 29%, compared to a 3.2% growth forecast for the Pharmaceuticals industry in Germany. Reported Earnings • Nov 07
Third quarter 2020 earnings released: EPS US$0.083 The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$83.4m (up 4.1% from 3Q 2019). Net income: US$3.92m (up 199% from 3Q 2019). Profit margin: 4.7% (up from 1.6% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 71% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Annuncio • Oct 30
Amphastar Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 06, 2020 Amphastar Pharmaceuticals, Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 06, 2020 Annuncio • Oct 07
Amphastar Pharmaceuticals Receives FDA Approval for Atropine Sulfate Injection Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration approved the Company’s Abbreviated New Drug Application for Atropine Sulfate injection 0.1mg/mL in the 10 mL Luer-Jet® Prefilled Syringe System. For the past 40 years, the Company has sold and marketed the product under the “grandfather” exception (now termed unapproved) to the FDA’s “Prescription Drug Wrap-Up” program. Net revenues for the Company’s Atropine Sulfate injection for the year ended December 31, 2019 were $12.2 million. Is New 90 Day High Low • Sep 23
New 90-day low: €15.80 The company is down 16% from its price of €18.80 on 25 June 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €49.06 per share. Annuncio • Jul 31
Amphastar Pharmaceuticals, Inc. to Report Q2, 2020 Results on Aug 06, 2020 Amphastar Pharmaceuticals, Inc. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 06, 2020 Annuncio • Jul 04
Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index Amphastar Pharmaceuticals, Inc.(NasdaqGS:AMPH) dropped from Russell 2000 Dynamic Index